Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

New Jersey-based biotechnology company, Grignard Pure LLC, a leader in developing next-generation indoor air treatment solutions for disease mitigation, indoor air quality and pandemic response, is ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Research photo from the National Cancer Institute, shared via Unsplash. (NCI Photo) When Luca Foschini, head of Seattle's ...

Lyon has confirmed the hiring of Paulo Fonseca as its new coach. Fonseca is replacing Pierre Sage, who was fired despite leading the French league club out of a crisis last season and having the team ...

A nanotechnology-based drug delivery system developed at UVA Health to save patients from repeated surgeries has proved to ...

Sage Therapeutics was in focus after it rejected Biogen's acquisition proposal. Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding ...

The Tyneside-based FTSE100 firm issued first quarter trading results for the three months to the end of December which showed ...

In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...